Results Proven In Clinical Research

Dr. Kenneth Brown and his team of scientists created Atrantil based on their understanding of how its three main natural botanicals would work together to relieve bloating, abdominal discomfort and changes in bowel habits—constipation, diarrhea or both. And to prove their formula was more than just a good idea, they tested it twice with real patients.

Northwestern University Feinberg School of Medicine Study

This study demonstrated the most ideal test for any over the counter solution regarding health issues such as bloating or associated gastrointestinal methane problems. First, the results demonstrated that 56% of all participants experienced adequate relief. Those results were measured against SEVEN categories of suffering. Second, this was a 100% independent, major university medical school test constructed without bias. Third, essentially there were no exclusionary criteria for participants. These are serious parameters for any solution to meet a challenge and Atrantil more than met expectations. The integrity of the design was trusted to a worldwide recognized leader in gastroenterology, the Principal Investigator, Darren Brenner, MD, FACG, AGAF, RFF. Dr. Brenner is a professor of medicine and surgery, an IDP Foundation Research Scholar, and the director of the Northwestern University Neurophysiology Program.

None of KBS Research, LLC and all associated partners had any influence, monetary or otherwise, regarding the study design, product acquisition, or analysis of results.

Double-Blind Trial

In a double-blind study of patients suffering from bloating, constipation and abdominal discomfort, Atrantil proved to be more than 88 percent effective in relieving symptoms. The leading two prescription therapies didn’t perform as well versus a placebo according to their own studies. The results of the trial were published in the Journal of Gastroenterology and Hepatology Research – September 21, 2015 pp. 1762-1767.

Open-Label Trial

The open-label trial targeted the toughest-to-treat patients to illustrate the efficacy of Atrantil. Before beginning the trial, patients qualified to participate only after failing to find relief from at least four prescription therapies. The trial showed that 80 percent of patients found relief after using Atrantil to control their bloating, constipation and abdominal discomfort. The results of the trial were published in the World Journal of Gastrointestinal Pharmacology and Therapeutics – August 6, 2016 pp. 463-468.